Description
Ivecop (Ivermectin) 12 mg
Ivecop 12 mg is an oral ivermectin medicine. Ivermectin is an antiparasitic agent used in human medicine for selected parasitic infections. The trade name Ivecop could not be independently verified from official sources, so this summary is based on the verified active ingredient, ivermectin.
Active Ingredient and Medicine Class
Active ingredient: ivermectin.
Medicine class: antiparasitic anthelmintic. It is a macrocyclic lactone with activity against certain nematodes and some ectoparasites.
Established Medical Uses
Official prescribing information for oral ivermectin tablets supports use in intestinal strongyloidiasis caused by Strongyloides stercoralis and onchocerciasis caused by Onchocerca volvulus. Published reviews also describe use in other parasitic diseases, but those uses are more variable by country and should not be assumed from the product name alone.
How It Works
Ivermectin works by interfering with nerve and muscle function in susceptible parasites. It acts on parasite chloride channels, which leads to paralysis and death of the organism. Human cells are much less affected because the drug targets parasite-specific pathways.
Important Safety Information
Oral ivermectin is contraindicated in people who are hypersensitive to ivermectin or any component of the product. In patients with onchocerciasis, treatment can trigger inflammatory reactions related to the death of microfilariae, including skin, eye and systemic reactions. Serious neurotoxicity has been reported, including confusion, altered consciousness and coma. Rare severe skin reactions and hepatitis have also been reported. Heavy Loa loa infection is an important risk factor for serious encephalopathy.
Clinically significant interactions and precautions have been described in prescribing information and pharmacology reviews, including the possibility that other medicines affecting drug transport or metabolism may change ivermectin exposure.
Possible Side Effects
Reported adverse effects include dizziness, nausea, vomiting, diarrhea, rash, itching, edema, low blood pressure, tachycardia and headache. More serious reactions can include severe skin reactions, hepatitis, neurotoxicity and encephalopathy in susceptible patients.
Scientific Evidence
PubMed-indexed reviews describe ivermectin as a well-established antiparasitic medicine with strong clinical use in strongyloidiasis and onchocerciasis, and a long history of generally low adverse-event rates when used appropriately. The evidence base is strongest for the approved parasitic indications, while evidence for additional uses is more limited and depends on the specific infection.
Medical Information Notice
This page is an educational summary based on sources available at the time of review and does not replace the official patient leaflet, prescribing information or individual professional assessment.
Medical Sources
- DailyMed / FDA label: IVERMECTIN tablet
- FDA label: STROMECTOL (ivermectin) Tablets
- P. González et al. “Ivermectin in human medicine, an overview of the current status of its clinical applications.” Current Pharmaceutical Biotechnology, 2012. PubMed article
